* AMP-activated protein kinase (AMPK) senses energetic stress and, in turn, promotes catabolic and suppresses anabolic metabolism coordinately to restore energy balance. We found that a diverse array of AMPK activators increased mTOR complex 2 (mTORC2) signaling in an AMPK-dependent manner in cultured cells. Activation of AMPK with the type 2 diabetes drug metformin (GlucoPhage) also increased mTORC2 signaling in liver in vivo and in primary hepatocytes in an AMPK-dependent manner. AMPK-mediated activation of mTORC2 did not result from AMPK-mediated suppression of mTORC1 and thus reduced negative feedback on PI3K flux. Rather, AMPK associated with and directly phosphorylated mTORC2 (mTOR in complex with rictor). As determined by two-stage in vitro kinase assay, phosphorylation of mTORC2 by recombinant AMPK was sufficient to increase mTORC2 catalytic activity toward Akt. Hence, AMPK phosphorylated mTORC2 components directly to increase mTORC2 activity and downstream signaling. Functionally, inactivation of AMPK, mTORC2, and Akt increased apoptosis during acute energetic stress. By showing that AMPK activates mTORC2 to increase cell survival, these data provide a potential mechanism for how AMPK paradoxically promotes tumorigenesis in certain contexts despite its tumor-suppressive function through inhibition of growth-promoting mTORC1. Collectively, these data unveil mTORC2 as a target of AMPK and the AMPK-mTORC2 axis as a promoter of cell survival during energetic stress.
INTRODUCTION

AMPK [adenosine monophosphate (AMP)-activated protein kinase]
functions as an ancestral energy sensor [reviewed in (1) (2) (3) (4) ]. During conditions of low cellular energy caused by glucose or nutrient depriva tion, exercise, or hypoxia, increased levels of AMP and ADP (adeno sine diphosphate) activate AMPK. AMPK functions in a heterotrimeric complex composed of one catalytic  subunit (a serine/threonine kinase), one scaffolding  subunit, and one regulatory  subunit. Vertebrates contain multiple  (1 and 2),  (1 and 2), and  (1 to 3) subunits and thus express 12 potential AMPK complexes whose distinct functions remain poorly defined. Upon energetic stress, AMP and ADP bind directly to the  subunit, causing an allosteric conformational change that activates AMPK by an incompletely defined mechanism involving increased ability of LKB1 or CaMKK to phosphorylate the activation loop site (Thr 172 ) on the AMPK  subunit, decreased dephosphorylation of the activation loop, and/or allosteric activation of phosphorylated AMPK [reviewed in (1) (2) (3) (4) ]. Upon activation, AMPK phosphorylates a diverse set of targets that redi rect cell metabolism toward ATP (adenosine triphosphate)-generating pathways (such as fatty acid oxidation, autophagy, glucose utiliza tion, and mitochondrial biogenesis) and away from ATP consuming anabolic pathways (such as ribosome biogenesis; fatty acid, lipid, and protein synthesis; gluconeogenesis; and cell growth and prolif eration) to restore energy balance.
The evolutionarily conserved kinase mTOR (mechanistic target of rapamycin) functions as an environmental sensor that responds to diverse cues to control fundamental cellular processes [reviewed in (5) (6) (7) (8) ]. mTOR forms the catalytic core of two signaling complexes with distinct regulation and function, mTOR complex 1 (mTORC1) and mTORC2. The mTOR partner raptor defines mTORC1 (a rapamycin sensitive complex) (9, 10) , whereas the mTOR partner rictor defines mTORC2 (a rapamycininsensitive complex) (11, 12) . Upon activa tion by hormones such as insulin and growth factors, mTORC1 promotes anabolic cell metabolism (including ribosome biogenesis; lipid, nucleotide, and protein synthesis; and cell growth) and sup presses catabolic cell metabolism (such as autophagy) (5) (6) (7) . Activa tion of mTORC1 requires sufficient levels of amino acids, which localize mTORC1 to lysosomal membranes near an important upstream activator [the guanosine triphosphatase (GTPase) Rheb] through the action of the ragulator/LAMTOR complex and Rag GTPases (13) (14) (15) [reviewed in (16, 17) ]. Insulinmediated activation of PI3K (phosphatidylinositol 3kinase) generates PIP 3 (phosphati dylinositol 3,4,5trisphosphate), which enables PDK1 (phosphoinositide dependent kinase 1) to activate Akt through phosphorylation of its activation loop site (Thr 308 ). In turn, Akt phosphorylates Tsc2 to inhibit the tumorsuppressive Tsc1/Tsc2 complex (TSC), whose GTPase activating protein (GAP) activity inhibits the GTPase Rheb on lyso somal membranes [reviewed in (18) (19) (20) ]. Thus, insulinPI3KAkt signaling promotes Rhebmediated activation of mTORC1 by sup pressing TSC function. The AGC kinase family member S6K1 (ri bosomal protein S6 kinase 1) is a welldefined mTORC1 substrate [reviewed in (5, 18, 21) ]. mTORC1mediated phosphorylation of the hydrophobic motif site (Thr 389 ), together with PDK1mediated phosphorylation of the activation loop site (Thr 229 ), activates S6K1. Various types of cell stress suppress mTORC1 function [reviewed in (22) ]. For example, AMPK inhibits mTORC1 during energetic stress through at least two mechanisms involving AMPKmediated phos phorylation of Tsc2 on an activating site and raptor on inhibitory sites (23, 24) .
The regulation and function of mTORC2 remains less well de fined than mTORC1. Growth factors activate mTORC2 in a PI3K dependent manner [reviewed in (7, 8) ]. PI3Kgenerated PIP 3 binds to the pleckstrin homology (PH)-domain on mSin1, an mTORC2 binding partner. PIP 3 binding to the mSin1 PHdomain allosteri cally relieves its suppressive effect on the mTOR kinase domain (25) . Beyond PI3K, upstream regulation of mTORC2 remains elusive. Curiously, TSC was reported to associate with and activate mTORC2 (26) (27) (28) . These data suggest that TSC inhibits mTORC1 but activates mTORC2. A distinct set of AGC kinases (Akt, SGK1, and PKC) represent substrates of mTORC2, with Akt representing the best defined target (7, 8, 19) . During growth factor signaling, mTORC2 phosphorylates Akt on its hydrophobic motif site (Ser 473 ) (29) . Al though Akt Thr 308 phosphorylation alone is sufficient to activate Akt, additional Ser 473 phosphorylation maximally activates Akt and modulates substrate specificity, directing Akt to some substrates (such as FoxO) but not others (such as Tsc2, PRAS40, and GSK3) (30, 31) . In many cell lines, knockdown of the mTORC2 components rictor or mSin1, and thus ablation of Akt Ser 473 phosphorylation, does not inhibit mTORC1 signaling (30, 31) . Thus, mTORC1 and mTORC2 signal in parallel in many cellular contexts. Constitutive mTORC1 signaling (such as upon inactivation of TSC) suppresses mTORC2 signaling through wellestablished negative feedback on PI3K flux mediated by inhibitory phosphorylation on IRS1 (32, 33) . mTORC2 also phosphorylates Akt on its turn motif site (Thr 450 ) in a growth factor-insensitive manner during the translation of nascent Akt on ribosomes, which facilitates Akt folding and stability (34) (35) (36) . mTORC2 promotes cell survival and metabolic homeostasis by in creasing glucose uptake in fat and muscle and reducing hepatic glucose production [reviewed in (6, 7, 37) ].
Here, we identify a previously unknown for activation of mTORC2, demonstrating that AMPK interacts with and phosphorylates mTORC2, resulting in its activation in response to energetic stress. This finding was unexpected, because mTORC2 has traditionally been thought to mediate insulin/PI3K signaling and because AMPK inhibits mTORC1. A diverse array of AMPKactivating agonists in creased mTORC2 signaling in cultured cells, and the AMPKactivating type 2 diabetes drug metformin (GlucoPhage) increased mTORC2 signaling in primary hepatocytes and in liver in vivo in an AMPK dependent manner. Our data show that the mechanism by which AMPK increases mTORC2 signaling is not through AMPKmediated suppression of mTORC1 signaling and thus reduced negative feedback on IRS1 and PI3K flux. We found that AMPK phosphorylated mTOR and rictor in vitro, which was sufficient to increase mTORC2 catalytic activity toward Akt. AMPK interacted with mTORC2 by coimmuno precipitation and increased mTOR phosphorylation in cultured cells and in vivo. During acute energetic stress, AMPK, mTORC2, and Akt suppressed apoptosis to promote cell survival. Our finding that AMPK activates mTORC2 directly may provide a mechanistic basis for the paradoxical role of AMPK as a tumor promoter (rather than a tumor suppressor) in certain contexts and its beneficial role in metabolism and glycemic control [reviewed in (38, 39) ].
RESULTS
AMPK phosphorylates mTOR within mTORC2, associates with mTORC2, and promotes mTORC2 signaling While investigating regulation of cellular mTOR signaling networks, we unexpectedly found that AICAR (5aminoimidazole4carboxamide ribonucleotide), an AMPmimetic compound that activates AMPK, increased the phosphorylation of Akt Ser 473 and the Akt downstream target FoxO1/3A Thr 24/32 in serumstarved mouse embryonic fibro blasts (MEFs). These data indicate that AICAR increases mTORC2 and Akt signaling (Fig. 1A) . Akt Ser 473 phosphorylation was sensi tive to the mTOR inhibitor torin1 (Fig. 1A) and the class I PI3K inhibitor BYL719 (Fig. 1B) (29, 40) , AICAR increased the phosphorylation of Akt on Thr 308 in a torin1 sensitive manner (Fig. 1A) .
By comparing MEFs lacking both AMPK1 and AMPK2 [double knockout (DKO)] to wildtype counterparts, we found that both basal and AICARstimulated phosphorylation of Akt Ser 473 was re duced in DKO MEFs (Fig. 1A) . When normalized to total Akt levels, which were slightly lower in AMPK DKO MEFs, AICAR increased the phosphorylation of Akt Ser 473 2.3fold in wildtype MEFs and 1.9fold in DKO MEFs (Fig. 1A, graph) . These data indicate that AICAR, which acts both dependently and independently of AMPK (41) (42) (43) (44) , increases mTORC2 signaling in a manner partially dependent on AMPK (Fig. 1A) . Consistent with mTORC2 also functioning as the Akt Thr 450 kinase that facilitates Akt stability (34, 35) , Akt Thr 450 phosphorylation was reduced modestly in AMPK DKO MEFs relative to wildtype MEFs, which likely explains the reduction in total Akt levels (Fig. 1A) . These data suggest that AMPKdependent and AMPKindependent targets of AICAR promote mTORC2 signaling to Akt in a manner that requires PI3K activity.
Finding that the AMPKactivating agonist AICAR increased mTORC2 signaling was intriguing because we had found, through an in vitro human kinome screen, that recombinant AMPK111 and AMPK211 phosphorylated mTOR on Ser 1261 ( fig. S1B ), a site whose phosphorylation promotes mTORC1 signaling (45) . We confirmed the kinome screen with classic in vitro kinase (IVK) assays. Recombinant active AMPK111 and AMPK211 phosphoryl ated a bacterially produced glutathione Stransferase (GST)-mTOR fragment in vitro ( fig. S1C ) and phosphorylated fulllength MycmTOR but not an S1261A mutant immunoprecipitated from transfected cells, thus confirming the phospho and site specificity of our phosphomTOR Ser 1261 antibody (Fig. 1D ) [see also (45) ]. AMPK111 and AMPK211 also phosphorylated rictorassociated mTOR, indicating that AMPK phosphorylates mTOR within mTORC2 (Fig. 1E) . The peptide sequence surrounding mTOR Ser 1261 resembles an AMPK consensus phosphorylation motif and the sequence surrounding raptor Ser 792 , a site phos phorylated by AMPK (Fig. 1F) (1, 24) . Coimmunoprecipitation assays demon strated that HAAMPK1 and HA AMPK2 associated with Flagrictor when coexpressed in human embryonic kidney (HEK) 293 cells (Fig. 1G ). These data demonstrate that AMPK directly phos phorylates mTOR on Ser 1261 within mTORC2 in vitro and associates with mTORC2 in intact cells.
We fig. S1D ), similar to phospho rylation of raptor Ser 792 as previously published (24) . As expected, AICAR de creased mTORC1 signaling to S6K1 in an AMPKdependent manner (Fig. 1, A and H). Analysis of rictor −/− MEFs re constituted with vector control or HA rictor indicated that intact mTORC2 was not required for AICAR to increase mTOR Ser 1261 phosphorylation (Fig. 1C) . Unexpectedly, we found that AICAR also increased mTOR Ser 1261 phosphorylation on raptorassociated mTOR (mTORC1) in an AMPKdependent manner (Fig. 1H) . Similar to AICAR, activation of AMPK by glucose withdrawal and phenformin, an analog of the type 2 diabetes drug metformin, also increased phosphoryl ation of Ser 1261 on rictorassociated mTOR in an AMPKdependent manner ( fig. S1 , The smallmolecule AMPK activator A769662 binds preferentially to the 1 subunit to activate 1containing, but not 2containing, AMPK complexes (47, 48) . Acute treatment of MEFs ( Fig. 2D ) and HEK293 cells ( fig. S2E ) with A769662 increased AMPK and mTORC2 signaling rapidly without reducing mTORC1 signaling. To deter mine whether AMPK was required for mTORC2 signaling in HEK293 cells, we knocked down either AMPK1 and AMPK2 together or AMPK1 in HEK293 cells with small interfering RNA (siRNA) before A769662 treatment. Knockdown of either subunit reduced mTORC2 signaling and expression of the other AMPK subunit (Fig. 2E ). To gether, these data demonstrate that AMPK is required for various AMPKactivating agonists to promote mTORC2 signaling in MEFs and HEK293 cells.
AMPK promotes mTORC2 signaling independently of mTORC1-mediated negative feedback
Chronic elevation (through TSC inactivation) or reduction (through raptor knockdown) of mTORC1 signaling decreases or increases PI3Kmediated signaling, respectively (32, 33) [reviewed in (19) ]. Observations such as these led to the identification of a negative feed back loop whereby mTORC1S6K1 signaling mediates inhibitory phosphorylation on IRS1 to reduce insulin/insulinlike growth fac tor 1 (IGF1)-mediated PI3K activation and signaling. Because AMPK suppresses mTORC1 signaling (19, 23, 24) , we designed experiments to dissociate AMPKmediated suppression of mTORC1 from AMPK mediated activation of mTORC2. That is, because mTORC2 signal ing requires PI3K, AMPKmediated suppression of mTORC1 could increase mTORC2 signaling indirectly through increased PI3K ac tivity rather than through a direct mechanism proposed here. We first compared how AICAR and rapamycin affected mTORC1 and mTORC2 signaling over time (10 to 240 min) in serumstarved MEFs. Although basal S6K1 Thr 389 phosphorylation was quite low in serum starved MEFs, AICAR and rapamycin reduced this level further (Fig. 3A) . Across the time course, AICAR increased Akt Ser 473 phos phorylation, whereas rapamycin did not. Moreover, AICAR failed to increase S6K1 phosphorylation on its PI3KPDK1-dependent activation loop site, Thr 229 , suggesting that AICAR treatment of serum deprived cells did not increase PI3K activity. Note that PI3KPDK1-mediated phosphorylation of S6K1 Thr 229 occurs independently of mTORC1mediated phosphorylation of S6K1 Thr 389 (49) and thus represents an appropriate readout for PI3K activity. The time course with which AICAR increased Akt Ser 473 phosphorylation correlated well with increased mTOR Ser 1261 phosphorylation and activation of AMPK, as monitored by phosphorylation of raptor Ser 792 and AMPK Thr 172 (Fig. 3A) . Thus, under conditions lacking serum growth factors, AICAR and rapamycin each reduced mTORC1 signaling to a similar extent, yet AICAR but not rapamycin increased mTORC2 signaling. These data suggest that AICAR does not increase mTORC2 signaling indirectly through AMPKmediated suppression of mTORC1 signal ing and subsequent reduction of negative feedback on PI3K. Note that in addition to an AICAR time course ( , and/or AMPK Thr 172 phospho rylation were conducted. The shortest treatment times that increased AMPK activity with subsequent activation of mTORC2 signaling and without substantial cell death were chosen for this work. For example, although 12hour glucose withdrawal increased Akt Ser 473 phosphoryl ation to a greater extent than 8 hours, it caused cell death ( fig. S3A ).
We next tested whether several other AMPKactivating agonists promote mTORC2 signaling independently of mTORC1 function by treating MEFs without and with rapamycin before AMPK activation. AICAR, glucose withdrawal, phenformin, or rotenone all increased Akt Ser 473 phosphorylation in both the absence and presence of rapamycin in MEFs (Fig. 3B) . We obtained similar results in serumstarved HEK293 cells treated with A769662 (Fig. 3B) . Because rapamycin is an al losteric inhibitor that suppresses mTORC1 signaling to various de grees depending on the substrate, we sought to exclude the possibility that AMPKmediated mTORC1 suppression increases mTORC2 signaling through a rapamycininsensitive mechanism. For example, although rapamycin completely blocks mTORC1mediated phos phorylation of S6K1 Thr 389 , it only partially blocks the phosphoryl ation of 4EBP1 and some, but not all, of the mTORC1 sites on Grb10, an adaptor protein that mediates negative feedback on insulin/IGF1-PI3K signaling (50) (51) (52) (53) [reviewed in (54, 55) ]. We therefore treated serumstarved HEK293 cells with siRNAmediated raptor knockdown without or with A769662. As expected, because of chronic mTORC1 inactivation and thus reduced negative feedback, knockdown of rap tor increased Akt Ser 473 phosphorylation in untreated cells relative to scrambled controls. Despite increased Akt Ser 473 phosphoryl ation in raptor knockdown cells, A769662 increased Akt Ser 473 phos phorylation further (Fig. 3C) . Last, A769662 increased mTORC2 signaling without reducing mTORC1 signaling in MEFs (Fig. 2E ) and HEK293 cells ( fig. S2E ). Together, these data dissociate AMPK mediated mTORC1 suppression from AMPKmediated mTORC2 activation.
We also noted that AICAR and insulin promoted mTORC2 sig naling with different kinetics: Insulin increased mTORC2 signaling quickly, reaching a maximal level at 10 min, whereas AICAR increased mTORC2 signaling more slowly (Fig. 3A) . AICAR and insulin in creased mTORC2 signaling additively over either agonist alone (Fig. 3D) . These data suggest that AMPK and insulin promote mTORC2 sig naling by different mechanisms. Moreover, they raise the intriguing idea that AMPK activators function as insulin sensitizers in vivo when used to treat type 2 diabetes by activating mTORC2 in parallel to and independently of insulin signaling.
AMPK promotes mTORC2 signaling in primary hepatocytes in culture and in tissue in vivo and ex vivo
To confirm that AMPK promotes mTORC2 signaling beyond im mortalized cells in culture, we analyzed primary mouse hepatocytes and liver tissue isolated from mice expressing or lacking AMPK1 and AMPK2 catalytic subunits through Cremediated excision of floxed AMPK alleles (56) . To generate these mice, we injected mice bearing floxed alleles of AMPK1 and AMPK2 with adenoassociated virus (AAV)-green fluorescent protein (GFP) or AAVCre viruses. Fourteen days after AAV infection, we isolated primary hepatocytes, serumstarved them overnight, and treated them without or with metformin, an analog of phenformin that activates AMPK and used clinically to treat type 2 diabetes, or AICAR. Alternately, 14 days after AAV infection, we dissected liver tissue from mice that had been fasted overnight and then injected acutely with saline control or metformin. Metformin (Fig. 4A) and AICAR (Fig. 4B) (Fig. 4, A and B) . We also found that metformin and insulin additively increased mTORC2 signaling in an AMPK dependent manner in hepatocytes (Fig. 4C ), similar to the additive effect of AICAR and insulin on mTORC2 signaling in MEFs (Fig. 3D) . We next tested whether activation of AMPK promotes mTORC2 signaling in tissue in vivo and ex vivo. Metformin administration to mice increased Akt Ser 473 and Thr 308 phosphorylation in liver ex pressing AMPK1/2 (AAVGFP) but not in liver with excised AMPK1/2 (AAVCre) (Fig. 4D and fig. S4A ). In fasted liver from control mice, S6K1 Thr 389 phosphorylation was almost undetectable, indicating low basal mTORC1 signaling, and metformin was unable to reduce mTORC1 signaling further. This observation is consistent with the increase in mTORC1 signaling induced by feeding after fast ing (57 
AMPK is sufficient to increase mTORC2 catalytic activity directly
We next sought to define the mechanism by which AMPK promotes mTORC2 signaling by asking whether AMPK phosphorylates mTORC2 to increase its intrinsic catalytic activity. We first performed a classic IVK assay by monitoring the ability of immunoprecipitated rictor/ mTOR (mTORC2) to phosphorylate recombinant Akt substrate. We treated serumstarved MEFs without or with AICAR after torin1 pretreatment and found that AICAR increased mTORC2mediated phosphorylation of HisAkt1 on Ser 473 in a torin1sensitive manner (Fig. 5A) . Moreover, stimulation of MEFs with insulin increased mTORC2 catalytic activity in our assay conditions. AICAR also in creased mTOR Ser 2481 autophosphorylation and Ser 1261 phosphoryl ation within mTORC2, and both AICAR and insulin increased mTORC2 signaling to Akt in intact cells. These data demonstrate that AICAR increases mTORC2 intrinsic catalytic activity toward itself and down stream substrate.
To ask whether AMPK per se was sufficient to increase mTORC2 catalytic activity directly, we developed a twostage mTORC2 IVK assay.
First, active recombinant AMPK1/1/1 was incubated in vitro with rictorassociated mTOR (mTORC2) (stage 1), and an IVK reaction was performed with ATP. Next, the mTORC2containing beads were washed (to remove AMPK1/1/1) and incubated in vitro with recombinant HisAkt1 and ATP (stage 2). Under our IVK conditions, incubation of mTORC2 with AMPK1/1/1 in stage 1 increased mTORC2mediated phosphorylation of HisAkt in stage 2 (Fig. 5B) . (Fig. 5B) . We noted that incubation of mTORC2 with AMPK1/1/1 during the stage 1 IVK reduced the electrophoretic mobility of rictor (Fig. 5C ). Because phos phorylation of rictor reduces its electro phoretic mobility (11, 58) , this finding suggests that AMPK phosphorylates rictor. Together, these data indicate that the cat alytic activity of AMPK is sufficient to increase mTORC2 catalytic activity, likely through phosphorylation of mTOR and/or its partner proteins (such as rictor).
Because (Fig. 6, A and B) . These agents activated AMPK to a similar ex tent in wildtype and mTOR A/A MEFs, as monitored by increased raptor Ser 792 phosphorylation. In hepatocytes, metformin also sim ilarly increased Akt Ser 473 phosphorylation in both genotypes, whereas it increased mTOR Ser 1261 phosphorylation only in wildtype but not (Fig. 6C ). These data reveal that mTOR Ser 1261 phosphorylation per se is not required for mTORC2 signal ing upon AMPK activation. These data do not rule out the possibil ity, however, that this phosphorylation event cooperates with other sites to promote mTORC2 signaling. Because AMPK phosphorylates mTORC2 components (such as mTOR and rictor) and its enzymatic activity is required for mTORC2 to phosphorylate Akt in vitro, we propose a model in which AMPK activates mTORC2 through mul tisite phosphorylation of mTOR and/or mTORC2 partner proteins.
The AMPK-mTORC2 axis promotes cell survival during acute energetic stress Because AMPK promotes cell survival during energetic stress (59), we next asked whether mTORC2 and Akt are required for suppres sion of cell death during energetic stress. We induced energetic stress using either AICAR treatment or glucose withdrawal (23, 59) and assessed apoptosis by measuring the cleavage of caspase 3 and poly(ADPribose) polymerase (PARP) by immunoblotting. AICAR treatment (Fig. 7A ) and glucose withdrawal (Fig. 7B) increased apoptosis in AMPK1/2 DKO MEFs to a greater extent than wild type MEFs. Inhibition of mTOR with torin1 increased apoptosis induced by these agents in wildtype MEFs under energetic stress. These data indicate that both AMPK and mTOR are required to suppress apoptosis during acute energetic stress. As expected, AICAR and glucose withdrawal activated AMPK (as monitored by mTOR (19, 31, 60) . Consistently, we found that AICAR (Fig. 7A ) and glucose withdrawal (Fig. 7B) (Fig. 7C) .
We next tested whether mTORC2 and Akt functions were re quired to suppress energetic stress-induced apoptosis. Apoptosis in response to AICAR or glucose withdrawal was higher in rictor −/− MEFs expressing vector control relative to those reconstituted with HArictor (Fig. 7, D fig. S6B ). We also confirmed that AMPK and mTORC2 suppress cell death upon energetic stress induced by AICAR by live cell fluo rescent microscopy using ReadyProbes reagents. Consistent with our analysis of apoptosis by Western blotting, we found that in response to energetic stress, inhibition of mTOR with torin1 (Fig. 7, F and G) or inactivation of mTORC2 by rictor knockout increased cell death (indicated by green cells; Fig. 7G ). Together, these data demonstrate that during energetic stress, activation of AMPK, mTORC2, and Akt promotes cell survival. Because the level of apoptosis was higher in AMPK1/2 DKO MEFs relative to wildtype MEFs treated with torin1, we propose a model in which AMPK promotes cell survival during acute energetic stress by both mTORC2Akt-dependent and mTORC2Akt-independent pathways (Fig. 7H) . In summary, our work demonstrates that AMPK phosphorylates mTOR and/or partner proteins to directly activate mTORC2, which functions to promote cell survival during acute energetic stress at least partially through Akt (Fig. 7I) .
DISCUSSION
Metabolic homeostasis requires that cells sense and integrate a diverse array of signals that fluctuate dynamically depending on environ mental conditions, the disruption of which contribute to pathologic conditions. AMPK and mTOR function as critical metabolic sensors [reviewed in (1, 3, (6) (7) (8) ]. AMPK activation in response to lowenergy conditions augments cell survival and promotes ATPgenerating metabolic processes to restore energy balance (23, 59) . mTOR within mTORC1 promotes anabolic and suppresses catabolic metabolism during nutrient and growth factor sufficiency, whereas mTOR within mTORC2 promotes cell survival and controls metabolism, both through Akt (7, 19, 31, 60) . AMPKmediated inhibition of mTORC1 during energetic stress thus facilitates coordination between catabolic and anabolic cell metabolism. Here, we report the unexpected find ing that AMPK, like the Tsc1/2 complex, activates mTORC2 directly, likely through multisite phosphorylation on mTOR and its mTORC2 partner proteins. Several AMPK activators increased the phosphorylation of Akt Ser 473 in serumstarved cells in a manner that required AMPK, mTOR, and mTORC2 function. Other groups have observed increased Akt Ser 473 phosphorylation upon AMPK activation (59, 61, 62) , although the mechanism was not investigated. Because inhibition of PI3K blocked AMPKmediated activated mTORC2 signaling in serumstarved cells, these data indicate that a minimal, basal level of PI3K activity is required for mTORC2 activation by AMPK. Because we could disso ciate AMPKmediated suppression of mTORC1 from AMPKmediated activation of mTORC2, mTORC1mediated negative feedback on ) and rictor (on unknown sites) within mTORC2 in vitro, and was sufficient to increase mTORC2 catalytic activity. These data support a model in which AMPK phosphorylates and activates mTORC2. Functionally, AMPK, mTOR, mTORC2, and Akt were all required to suppress apoptosis in response to acute energetic stress. Because we found that AMPK activation and insulin increased Akt Ser 473 phosphoryl ation additively in both MEFs and primary hepatocytes, an effect observed by others (61, 63) , we propose that insulin and AMPK sig nal in parallel to increase mTORC2 function (Fig. 7I) . Thus, mTORC2 functions as an effector not only of insulin/PI3K signaling but also of AMPK.
Analysis of primary fibroblasts and hepatocytes isolated from CRISPRgenerated mTOR S1261A knockin mice (mTOR A/A ) indi cated that the phosphorylation of mTOR Ser 1261 (within the centrally located mTOR FATdomain) was not essential for mTORC2 sig naling in response to AMPK activation. However, this phosphoryl ation event reflected the action of AMPK on mTORC2, and we speculate that it contributed to mTORC2 activation in cooperation with other sites. We found that recombinant AMPK phosphorylated rictor in vitro. Moreover, a quantitative phosphoproteomic study predicted that rictor is an AMPK substrate (64) . It will be important in the future to identify the critical set of AMPK phosphorylation sites on mTOR and/or partner proteins responsible for mTORC2 activation. Because of tight coupling between AMPK activation and mTOR Ser 1261 phosphorylation across our experiments, we propose that the phosphorylation of mTOR Ser 1261 represents a new biomarker to monitor AMPK activity in intact cells, similar to the phosphoryl ation of raptor Ser 792 or ACC (acetyl-coenzyme A carboxylase) Ser
79
. Determining where in the cell AMPK activates mTORC2 remains an unresolved question. Because late endosomal/lysosomal mem branes serve as a subcellular site important for AMPK activation (65) , AMPKmediated mTORC2 activation may occur on this membrane platform. Consistent with this idea, analysis of a reporter construct engineered to monitor Akt Ser 473 phosphorylation localized active mTORC2 to early and late endosomes, as well as to the plasma membrane and mitochondria (66) . Consistent with mitochondria as a potential site important for mTORC2 regulation and/or function, fluorescent microscopy localized rictor to mitochondriaassociated endoplasmic reticulum (ER) membranes (67) . Although our data may initially present a paradox-AMPK in hibits mTORC1 but activates mTORC2-they fit with emerging data revealing a complex interplay between AMPK and mTOR in the control of cell and animal physiology. Huang et al. demonstrated that the mTORC1 inhibitory Tsc1/2 complex interacts with mTORC2 and is required for insulin and other growth factors to increase mTORC2mediated Akt Ser 473 phosphorylation in cells (26, 68) . Like our work on AMPKmTORC2, Tsc1/2mediated activation of mTORC2 occurs independently of mTORC1mediated negative feedback (26) . Moreover, recombinant Tsc1/2 stimulates the IVK activity of mTORC2 directly, similar to our work with AMPK (27) . Thus, both AMPK and Tsc1/2 inhibit mTORC1 but activate mTORC2. Moreover, the vATPaseragulator/LAMTOR complex, which en ables mTORC1 activation on lysosomal membranes during amino acid sufficiency by driving RagGTP loading (13) (14) (15) 69) , also activates AMPK on lysosomal membranes during glucose deprivation (65) MEFs stably expressing vector control or HA-rictor were serum-starved and treated with AICAR as in (A) or subjected to glucose withdrawal (24 hours). Blots are representative of three independent experiments. (F) WT and AMPK1/2 DKO MEFs were treated with AICAR (5 hours) as in (A). ReadyProbes cell viability reagents were added to the culture medium, and live cells were imaged using blue [4′,6-diamidino-2-phenylindole (DAPI)] and green [fluorescein isothiocyanate (FITC)/GFP] filters on an inverted epifluorescence microscope. Cell death (%) was calculated using the ratio of green, nonviable cells over total blue cells (includes green cells). Graph represents the mean ± SD of n = 4 experiments, in which n = 300 cells were counted per treatment in each experiment. Statistical significance was tested by ANOVA followed by pairwise Tukey's post hoc tests (**P < 0.001). (G) rictor −/− MEFs rescued with HA-rictor or vector control (Vector) were treated with AICAR (5 hours) as in (A). ReadyProbes cell viability reagents were added to the culture medium, and cells were imaged as in (F). Cell death (%) was calculated as in (F). Graph represents the mean ± SD of n = 3 experiments, in which n = 250 to 300 cells were counted per treatment in each experiment. Statistical significance was tested by ANOVA (**P < 0.001) followed by pairwise Tukey's post hoc tests. (H) AMPK promotes cell survival during acute energetic stress by both mTORC2-dependent and mTORC2-independent pathways. (I) AMPK phosphorylates mTOR and/or partner proteins directly to increase mTORC2 catalytic activity, which functions to promote cell survival during acute energetic stress through Akt.
[reviewed in (70, 71) ]. Dual activation of AMPK and mTORC1 by vATPaseragulator/LAMTOR has been proposed to control a switch between anabolic and catabolic cell metabolism. Because conventional wisdom holds that AMPK inhibits mTORC1 during energetic stress, these data reveal a more complicated relationship between AMPK and mTOR than previously appreciated. In addi tion, glucose deprivation activates AMPK independently of AMP and ADP levels by a glucosesensing mechanism involving fructose1, 6bisphosphate, aldolase, and vATPaseragulator/LAMTOR (72), thus adding to the emerging complexity of AMPK regulation. Be cause AMPK inhibits mTORC1 signaling (in response to energetic stress) (23, 24) and because our previous work indicated that mTOR Ser 1261 phosphorylation promotes mTORC1 signaling (in the absence of energetic stress) (45), we were surprised to find here that AMPK increases Ser 1261 phosphorylation on raptorassociated mTOR (mTORC1) [as well as on rictorassociated mTOR (mTORC2)]. Perhaps an AMPK related kinase phosphorylates mTOR Ser 1261 within mTORC1 to pro mote mTORC1 activation during energy sufficiency. Our kinome screen found that AMPKrelated kinases called SIKs (saltinducible kinases) and MARKs (microtubule affinity-regulating kinases) phos phorylate mTOR Ser 1261 in vitro ( fig. S1A ). We speculate that perhaps in response to energetic stress, AMPKmediated inhibitory phos phorylation of Tsc2 and raptor dominantly suppresses mTORC1 signaling despite activating phosphorylation of mTOR Ser 1261 within mTORC1. Future work should investigate roles for AMPK, SIK, and MARK in mTORC1 regulation in response to mTOR Ser 1261 phosphorylation.
Our finding that AMPK activated mTORC2 and the prosurvival kinase Akt fits well with defined roles for these kinases in the pro motion of cell survival and tumorigenesis. Traditionally, AMPK has been thought to function as a tumor suppressor due to its phospho rylation (on Thr
172
) and activation by LKB1, the tumor suppressor protein inactivated in the PeutzJeghers benign tumor syndrome (59, 73, 74) . In addition, AMPK inhibits mTORC1, a driver of cell growth and proliferation. Consistent with this tumorsuppressive role, retrospective metaanalysis of type 2 diabetic patients treated with metformin indicates reduced cancer incidence (75, 76) . However, AMPK can also function as a tumor promoter that promotes cell survival during metabolic stress (59, 77, 78) . Mutational inactiva tion of LKB1 renders non-small cell lung carcinoma cells and tu mors bearing oncogenic KRas more susceptible to apoptosis caused by phenformininduced metabolic stress (78) . These data suggest that metabolic drugs may function as selective anticancer agents by driving apoptosis in the absence of sufficient survival signaling. Moreover, they suggest that AMPK functions as a tumor promoter in certain contexts, perhaps by promoting survival of cancer cells deep within solid tumors experiencing metabolic stress (such as glucose depri vation and hypoxia) (38, (79) (80) (81) (82) . Our data demonstrate that AMPK, mTORC2, and Akt promote cell survival during energetic stress.
AMPK and mTORC2 control glucose metabolism in similar ways. AMPK activation produces insulinsensitizing and antihyperglycemic effects in cultured cells and in vivo. This knowledge has made AMPK an attractive therapeutic target for treatment of insulin resistance and type 2 diabetes, thus spurring the ongoing development of AMPK activating small molecules such as A769662, 991, MT 6378, MK8722, and PF739 (47, (83) (84) (85) (86) . The AMPKactivating drug metformin (trademarked as GlucoPhage) is the most widely prescribed drug worldwide for treatment of type 2 diabetes because of its ability to suppress hepatic glucose production and improve systemic glycemic control. However, metformin mediates beneficial metabolic effects independently of AMPK as well (76, 87) . Our finding that AICAR and insulin increase mTORC2 signaling additively may explain, in part, how AMPK activation produces insulinmimetic effects in vivo. In the liver, both AMPK and mTORC2 suppress gluconeogenesis and thus hepatic glucose production, whereas in muscle and fat, they enhance insulin sensitivity and promote glucose uptake (4, 7, 86, (88) (89) (90) (91) (92) . Thus, AMPK and mTORC2 functionally align in controlling glucose metabolism. Together, our data support the concept that although the AMPKmTORC2 axis may improve metabolic control, it may also promote tumorigenesis in certain contexts. The identification of mTORC2 as a new target of AMPK that promotes cell survival and possibly glucose homeostasis advances and shifts our under standing of the complex relationship between AMPK and mTOR and their roles in health and disease. (#2083), raptor (#2280), S6K1 PThr 389 (#9234), GST (#2625), cleaved caspase 3 (#9664), cleaved PARP (#9544), Erk1/Erk2 (#9102), actin (#4967), and tubulin (#2144). mTOR PSer 2481 was from Millipore (#09343). S6K1 PThr 229 antibody was from Abcam (#ab59208). The following custom polyclonal antipeptide antibodies were generated by us with the aid of Covance, as described previously (45): mTOR PSer 1261 (amino acids 1256 to 1266; rat), rictor (amino acids 6 to 20; human), and S6K1 (amino acids 485 to 502; rat 70kDa isoform). Donkey antirabbit-HRP secondary antibody was from Jackson ImmunoResearch (#711095152), and sheep antimouse-HRP was from GE Healthcare (#NA931V). Plasmids HAAMPK1, HAAMPK1, MycAMPK1, and MycAMPK1 expression plasmids were obtained from K. Inoki (University of Michigan, Ann Arbor, MI). pRK5/MycmTOR plasmid was from Addgene (#186) (originally from D. Sabatini, MIT and the Whitehead Institute); pCMV/Flagrictor plasmid was purchased from the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (University of Dundee). pCI/HArictor was from E. Jacinto (Rutgers University, New Brunswick, NJ).
MATERIALS AND METHODS
Materials
Generation of recombinant GST-mTOR for IVK assays
A fragment of mTOR encoding amino acids 1223 to 1271 (rat) was subcloned via polymerase chain reaction (PCR) into vector pGEX 20T for production of GST fusion proteins in the bacterial strain BL21(DE3) LysS. The following primers were used to PCR amplify the mTOR fragment: primer 1, 5′gacgggattcgctgatgaagaagaagac ccttt3′; primer 2, 5′gattgaattcgacccttctggcagctcc3′. GST mTOR was affinitypurified on glutathionesepharose beads via a standard protocol and dialyzed against 10 mM tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, dithiothreitol (DTT; 154 mg/liter), and 5% glycerol.
In vitro kinome screen
The in vitro kinome screen was performed in collaboration with Invitrogen/Life Technologies. About 300 recombinant human ki nases arrayed on a 384well plate were incubated with GSTmTOR substrate (0.125 mg/ml) in reactions containing 25 nM recombinant kinases and 1 mM ATP [50 mM Hepes (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, and 0.01% Brij35]. Reactions were incubated at room tem perature for 1 hour. Dot blots of the kinase reactions were imaged after incubation with PmTORSer 1261 primary antibody and Alexa Fluor 488 antirabbit secondary antibody.
IVK assays
IVK assays were performed by incubating recombinant GSTmTOR (~100 ng) or immunoprecipitated MycmTOR substrate with ATP (250 M) and recombinant (100 ng/reaction) AMPK1/1/1 or AMPK2/1/1 in 15 l of kinase buffer containing 10 mM tris (pH 7.5), 10 mM MgCl 2 , 100 mM NaCl, and 1 mM DTT. Reactions were in cubated at 30°C for 30 min and stopped by addition of sample buffer followed by incubation at 95°C for 10 min. Samples were re solved on SDS-polyacrylamide gel electrophoresis (PAGE), trans ferred to PVDF membrane, and immunoblotted with mTOR Ser 1261 antibodies. For drug pretreatments, recombinant kinases were pre incubated (30 min) with torin1 (5 M; from D. Sabatini), with com pound C (0.5 mM; #171261, Millipore/Calbiochem), or in kinase buffer on ice for 30 min.
mTORC2 IVK assays were performed as described (26) . Briefly, rictor was immunoprecipitated from serumstarved MEFs either unstimulated or stimulated with AICAR (2.5 mM) (2 hours) or in sulin (100 nM; 30 min) (about one 10cm plate for each immuno precipitate). Immunoprecipitates were preincubated with torin1 (5 M) on ice (30 min) and then incubated with ATP (250 M) and recom binant Akt1 (100 ng/reaction) in 15 l of kinase buffer containing 25 mM Hepes, 100 mM potassium acetate, and 1 mM MgCl 2 at 30°C for 30 min and stopped by addition of sample buffer followed by incubation at 95°C for 10 min.
To perform twostage mTORC2 IVK assays, rictor was immuno precipitated from serumstarved MEFs, washed three times with CHAPS lysis buffer and once with kinase buffer A [10 mM tris (pH 7.5), 10 mM MgCl 2 , 100 mM NaCl, and 1 mM DTT], and incubated with recombinant AMPK111 (100 ng/reaction) in 15 l of kinase buffer A for 30 min at 30°C (stage 1). Immediately after the first IVK reactions, tubes were placed on ice and washed twice with kinase buffer B (25 mM Hepes, 100 mM potassium acetate, and 1 mM MgCl 2 ), incubated with ATP (250 M) and recombinant Akt1 (100 ng/reaction) in 15 l of kinase buffer B at 30°C for 30 min, and stopped by addition of sample buffer followed by incubation at 95°C for 10 min (stage 2).
Cell culture, transfection, and drug treatments Wildtype and AMPK1/2 DKO MEFs were from B. Viollet (Inserm, Paris, France); HEK293 cells were from the American Type Culture Collection. All cell lines were cultured in DMEM that contained high glucose (4.5 g/liter), glutamine (584 mg/liter), and sodium pyruvate (110 mg/liter; Life Technologies/Invitrogen) supplemented with 10% fetal bovine serum (FBS; Gibco/Invitrogen) and incubated at 37°C in a humidified atmosphere containing 5% CO 2 . HEK293 cells were transfected according to the manufacturer's directions using TransIT LT1 (Mirus Bio). Cells were lysed ~24 to 48 hours after transfection. To effect serum starvation, cells were washed twice with DMEM/ 20 mM Hepes (pH 7.2) and cultured in this medium for ~20 hours.
Cells were then stimulated with AICAR (2.5 mM; 1 to 2 hours; #9944, CST), phenformin (2 mM; 90 min; #P7045, Sigma), rotenone (250 ng/ml; 60 min; #150154, MP Biomedical), A769662 (100 M; 5 to 30 min; #3336, Tocris Bioscience), antimycin A (10 mM; 60 min; #A8674, Sigma), oligomycin A (10 g/ml; 60 min; #75351, Sigma), metformin (2 mM; 2 hours; #PHR1084, Sigma), and insulin (100 nM; 30 min; #12585, Invitrogen). The following additional drugs not de scribed above were used: rapamycin (20 ng/ml; #553210, Calbiochem), torin1 (100 nM; shared by D. Sabatini), compound C (25 M; #171261, Calbiochem), BYL719 (#1020, Selleck), and MK2206 (10 M; #1078, Selleck).
Cell lysis, immunoprecipitation, and immunoblotting
Unless indicated otherwise, cells were washed twice with icecold phosphatebuffered saline (PBS) and lysed in icecold buffer A con taining 0.5% NP40 and 0.1% Brij35, as described (45) . To main tain the detergentsensitive mTORraptor interaction, cells were lysed in icecold buffer A containing 0.3% CHAPS. Lysates were spun at 13,200 rpm for 5 min at 4°C, and the postnuclear supernatants were collected and incubated on ice (15 min). The Bradford assay was used to normalize protein levels for immunoprecipitation and immunoblot analysis. For immunoprecipitation, wholecell lysates were incubated with antibodies for 2 hours at 4°C, followed by incu bation with protein G or ASepharose beads for 1 hour. Sepharose beads were washed three times in lysis buffer and resuspended in 1× sample buffer. Samples were resolved on SDSPAGE and trans ferred to PVDF membranes in Towbin transfer buffer containing 0.02% SDS, as described (45) . Immunoblotting was performed by blocking PVDF membranes in trisbuffered saline (TBS; pH 7.5) with 0.1% Tween 20 (TBST) containing 3% nonfat dry milk, as de scribed (45) , and incubating the membranes in TBST with 2% bovine serum albumin (BSA) containing primary antibodies or secondary HRPconjugated antibodies. Blots were developed by ECL and de tected digitally with a ChemiDocIt System (UVP).
Viral transduction rictor
−/− MEFs stably expressing HArictor and AMPK1/2 DKO MEFs stably expressing HAAMPK1 were generated by lentiviral transduction. HAtagged rictor cDNA or HAAMPK1 complemen tary DNA (cDNA) was subcloned into a modified lentiviral vector, pHAGEPuroMCS (pPPM; modified by A. Hudson, Medical College of Wisconsin) (93) . Lentivirus particles were packaged in HEK293T cells by cotransfection with empty pPPM vector, pPPM/HArictor, or pPPM/HA/ AMPK1 together with pRC/Tat, pRC/Rev, pRC/ gagpol, and pMD/VSVG using Mirus TransITLT1 transfection reagent. Supernatants containing viral particles were collected 48 hours after transfection and filtered through a 0.45m filter. rictor MEFs or AMPK1/2 DKO MEFs were infected with fresh viral supernatants containing polybrene (8 g/ml). Twentyfour hours after infection, cells were selected in DMEM/10% FBS supplemented with puromycin (3 g/ml). Generation of genetically modified mice bearing a germline mTOR knock-in S1261A allele using CRISPR-Cas9 genome editing technology A 20nucleotide (nt) guide sequence targeting genomic mTOR upstream of Ser 1261 was subcloned into pX330. Forward sequence: 5′caccgacctgccttttggaggttga; reverse sequence: 5′aaactcaacctc caaaaggcaggac. The following singlestranded oligonucleotide served as repair template, which includes the targeted sequence (underlined), left and right homology arms, and the S1261A mutation (also underlined; AGC to GCG): 5′gaccctttgatttaccagcatcgaatgcta aggagcagccagggagatgccctggccagtggaccagttgagacaggacccat gaagaaactgcatgtcGCGaccatAaaTctTcaaaaggcaggtccattgtttccag ggggattgggaagcagggctctgttttttttctctcattca3′.
RNA interference
The repair template also included several silent mutations (capi talized) to prevent retargeting of edited genomic signals and a new Nru I restriction site ([tcGCGa]) to facilitate genotyping. The guide RNA (gRNA) targeting plasmid (pX330mTOR) and the repair tem plate were comicroinjected into singlecell fertilized mouse oocytes and implanted into a pseudopregnant mouse. Heterozygous founders were identified through Nru I restriction of genomic DNA. To con firm corecombination of both the Nru I site and the S1261A muta tion, the genomic region was TOPOcloned and sequenced.
The following PCR primers were used for TOPO cloning: 5′GTT GAAATCCTGGCTCTTGC3′ (forward) and 5′GCAGGATTTA CACGTTTAA3′ (reverse).
To generate mTOR A/A homozygous mice, mice heterozygous for mTOR S1261A were mated (mTOR + /mTOR A x mTOR + /mTOR A ). These mice were generated with the assistance of the Molecular Ge netics Core of the MDRC (Michigan Diabetes Research Center) and the University of Michigan Transgenic Core. For genotyping, a ~600nt fragment of genomic DNA surrounding the mTOR Ser 1261 locus was PCRamplified and digested with Nru I. The following PCR primers were used for genotyping: 5′GTTGAAATCCTG GCTCTTGC3′ (forward) and 5′GCAGGATTTACACGTTTAA3′ (reverse).
Isolation of MEFs
MEFs were isolated as described previously (94) .
Cre-mediated excision of floxed AMPK1 and AMPK2 in vivo Mice (C57BL6) were housed in a specific pathogen-free facility with a 12hour light/12hour dark cycle and given free access to food and water. All animal use was in compliance with the Institute of Labo ratory Animal Research Guide for the Care and Use of Laboratory Animals and approved by the University Committee on Use and Care of Animals at the University of Michigan. Mice bearing floxed AMPK1 and AMPK2 (AMPK f/f), generated by S. Morrison (UT Southwestern Medical Center) as described (56) and shared by K. Inoki (University of Michigan Medical School), were injected through the tail vein with AAVGFP (AAV8TBG.PI.eGFP.WPRE. bGH) or AAVCre (AAV8.TBG.PPI.Cre.rBG) (1.5 × 10 to 10 plaque forming units per mouse) (Penn Vector Core). After 14 days, pri mary mouse hepatocytes were isolated or mice were administered metformin, as described below.
Isolation of primary mouse hepatocytes
Primary mouse hepatocytes were isolated from 9 to 12weekold mice, as described previously (95) . Briefly, the liver was perfused with Earle's balanced salt solution (Invitrogen) containing 0.5 mM EGTA for 5 min and perfused with type I collagenase (200 U/ml; Worthington) via the inferior vena cava for 5 min. After dissection, hepatocytes were released by scattering, passed through a 100m cell strainer, and then spun at 50g for 1 min. The pellet was resus pended in DMEM and then spun at 50g for 10 min in a Percoll gradient to remove dead hepatocytes. Viable cells were washed with DMEM at 50g for 10 min and checked by trypan blue staining. Primary mouse hepatocytes were plated in DMEM with 10% FBS.
In vivo metformin treatment and analysis
Male mice (8 weeks old) were injected intraperitoneally with PBS or metformin (250 mg/kg body weight; 1 hour). Livers were immediately flashfrozen in liquid nitrogen and homogenized in radioimmuno precipitation assay (RIPA) lysis buffer [50 mM trisHCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM NaF] for Western blot analysis.
Ex vivo incubation of rat soleus muscle
After an overnight fast, male Wistar rats were anesthetized [with an intraperitoneal injection of sodium pentobarbital (50 mg/kg)], and their soleus muscles were isolated. The muscles were longitu dinally dissected into strips that underwent a twostep incubation (step 1 = 20 min; step 2 = 120 min) in vials containing oxygenated KrebsHenseleit buffer (KHB) along with BSA (0.1%) and glucose (8 mM) that were placed in a heated (35°C) water bath. During step 2, muscle strips were transferred to a second flask including KHB/BSA/glucose along with AICAR (2 mM), A769662 (200 M), or neither compound. After step 2, muscles were immediately freezeclamped using aluminum tongs cooled to the temperature of liquid nitrogen and homogenized in RIPA lysis buffer, as de scribed above.
Cell viability assay
Cells were seeded on 35mm polylysinecoated glass bottom plates, serumstarved (20 hours), pretreated with 100 nM torin1, and treat ed with 2.5 mM AICAR (5 hours). Cell viability was assessed by adding ReadyProbes reagents (Thermo Fisher Scientific; catalog no. R37609) for the last 15 min of incubation, according to the manu facturers' instructions. NucBlue Live reagent (Hoechst 33342) stains the nuclei of all cells, whereas NucGreen Dead stains the nuclei of dead cells with compromised plasma membranes. Images were col lected on an inverted epifluorescence microscope (Nikon TE2000E) equipped with a Photometrics CoolSnap HQ camera and analyzed using ImageJ (National Institutes of Health).
Image editing
Adobe Photoshop was used for image preparation using only levels, brightness, and contrast and changing these parameters equivalent ly over the entire image.
Statistical analysis
Results are presented as means ± SD. Significance of the difference between two conditions was determined by unpaired Student's t test. To determine significance of the difference between multiple condi tions, oneway ANOVA followed by Tukey's post hoc tests was used. Values of P < 0.05 were considered significant.
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